Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Evaluation of In Situ Hardening β-Tricalcium Phosphate/Poly(lactic-co-glycolide) Bone Substitute Used in Edentulous Ridge Preservation for Late Implant Placement: Case Series.

Geivelis MM, Lingen MW, Takemura A.

Clin Adv Periodontics. 2019 Jun;9(2):55-58. doi: 10.1002/cap.10050. Epub 2018 Nov 12.

PMID:
31498573
2.

Plasmacytoid cells in salivary pleomorphic adenoma: an alternative interpretation of their immunohistochemical characteristics highlights function and capability for epithelial-mesenchymal transition.

Koutlas IG, Dolan M, Lingen MW, Argyris PP.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Feb 7. pii: S2212-4403(19)30109-9. doi: 10.1016/j.oooo.2019.01.081. [Epub ahead of print]

PMID:
31400990
3.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE.

Ann Oncol. 2019 Jun 5. pii: mdz171. doi: 10.1093/annonc/mdz171. [Epub ahead of print] No abstract available.

PMID:
31168601
4.

Mucoepidermoid Carcinoma: A Comparison of Histologic Grading Systems and Relationship to MAML2 Rearrangement and Prognosis.

Cipriani NA, Lusardi JJ, McElherne J, Pearson AT, Olivas AD, Fitzpatrick C, Lingen MW, Blair EA.

Am J Surg Pathol. 2019 Jul;43(7):885-897. doi: 10.1097/PAS.0000000000001252.

PMID:
31021855
5.

A History of Innovations in the Diagnosis and Treatment of Oral and Head and Neck Cancer.

Polverini PJ, Lingen MW.

J Dent Res. 2019 May;98(5):489-497. doi: 10.1177/0022034519833645.

PMID:
31008698
6.

Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.

Clin Cancer Res. 2018 Dec 1;24(23):6099. doi: 10.1158/1078-0432.CCR-18-3194. No abstract available.

PMID:
30510088
7.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE.

Ann Oncol. 2019 Feb 1;30(2):297-302. doi: 10.1093/annonc/mdy522.

PMID:
30481287
8.

Triple O Content Innovations and New Section Editors.

Lingen MW.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Jan;127(1):1-2. doi: 10.1016/j.oooo.2018.10.004. Epub 2018 Oct 21. No abstract available.

PMID:
30473395
9.

Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy.

Lee SS, Bindokas VP, Lingen MW, Kron SJ.

Lab Invest. 2019 Sep;99(9):1400-1413. doi: 10.1038/s41374-018-0156-y. Epub 2018 Nov 6.

10.

Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline.

Fakhry C, Lacchetti C, Rooper LM, Jordan RC, Rischin D, Sturgis EM, Bell D, Lingen MW, Harichand-Herdt S, Thibo J, Zevallos J, Perez-Ordonez B.

J Clin Oncol. 2018 Nov 1;36(31):3152-3161. doi: 10.1200/JCO.18.00684. Epub 2018 Sep 6. Erratum in: J Clin Oncol. 2019 Jan 20;37(3):261.

PMID:
30188786
11.

Histological features and prognostic significance of treatment effect in lymph node metastasis in head and neck squamous cell carcinoma.

Scherpelz KP, Wong AC, Lingen MW, Taxy JB, Cipriani NA.

Histopathology. 2019 Jan;74(2):321-331. doi: 10.1111/his.13742. Epub 2018 Nov 4.

PMID:
30144145
12.

Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.

Saintigny P, William WN Jr, Foy JP, Papadimitrakopoulou V, Lang W, Zhang L, Fan YH, Feng L, Kim ES, El-Naggar AK, Lee JJ, Mao L, Hong WK, Lingen MW, Lippman SM.

J Natl Cancer Inst. 2018 Mar 1;110(3). doi: 10.1093/jnci/djx186.

13.

Authors' response.

Lingen MW.

J Am Dent Assoc. 2018 Apr;149(4):233-234. doi: 10.1016/j.adaj.2018.02.014. No abstract available.

PMID:
29599016
14.

Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies.

Drazer MW, Kadri S, Sukhanova M, Patil SA, West AH, Feurstein S, Calderon DA, Jones MF, Weipert CM, Daugherty CK, Ceballos-López AA, Raca G, Lingen MW, Li Z, Segal JP, Churpek JE, Godley LA.

Blood Adv. 2018 Jan 23;2(2):146-150. doi: 10.1182/bloodadvances.2017013037.

15.

Adjuncts for the evaluation of potentially malignant disorders in the oral cavity: Diagnostic test accuracy systematic review and meta-analysis-a report of the American Dental Association.

Lingen MW, Tampi MP, Urquhart O, Abt E, Agrawal N, Chaturvedi AK, Cohen E, D'Souza G, Gurenlian J, Kalmar JR, Kerr AR, Lambert PM, Patton LL, Sollecito TP, Truelove E, Banfield L, Carrasco-Labra A.

J Am Dent Assoc. 2017 Nov;148(11):797-813.e52. doi: 10.1016/j.adaj.2017.08.045.

PMID:
29080605
16.

Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association.

Lingen MW, Abt E, Agrawal N, Chaturvedi AK, Cohen E, D'Souza G, Gurenlian J, Kalmar JR, Kerr AR, Lambert PM, Patton LL, Sollecito TP, Truelove E, Tampi MP, Urquhart O, Banfield L, Carrasco-Labra A.

J Am Dent Assoc. 2017 Oct;148(10):712-727.e10. doi: 10.1016/j.adaj.2017.07.032.

PMID:
28958308
17.

Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.

Can NT, Lingen MW, Mashek H, McElherne J, Briese R, Fitzpatrick C, van Zante A, Cipriani NA.

Head Neck Pathol. 2018 Mar;12(1):95-104. doi: 10.1007/s12105-017-0833-y. Epub 2017 Jul 5.

18.

Granulocyte colony-stimulating factor blockade enables dexamethasone to inhibit lipopolysaccharide-induced murine lung neutrophils.

Banuelos J, Cao Y, Shin SC, Bochner BS, Avila P, Li S, Jiang X, Lingen MW, Schleimer RP, Lu NZ.

PLoS One. 2017 May 19;12(5):e0177884. doi: 10.1371/journal.pone.0177884. eCollection 2017.

19.

Expanding the Research Capacity of Dental Schools: Are We There Yet?

Polverini PJ, Lingen MW.

J Dent Res. 2017 Jan;96(1):8-9. doi: 10.1177/0022034516680557. No abstract available.

PMID:
28033062
20.

Changing of the guard.

Lingen MW.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jan;123(1):1-2. doi: 10.1016/j.oooo.2016.10.014. Epub 2016 Nov 1. No abstract available.

PMID:
27938941
21.

Screening for oral cancer-a perspective from the Global Oral Cancer Forum.

Speight PM, Epstein J, Kujan O, Lingen MW, Nagao T, Ranganathan K, Vargas P.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jun;123(6):680-687. doi: 10.1016/j.oooo.2016.08.021. Epub 2016 Sep 9. Review.

PMID:
27727113
22.

Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.

Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, Kocherginsky M, Villaflor VM, Cohen EE, Haraf DJ, Vokes EE.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):21-9. doi: 10.1016/j.ijrobp.2016.04.030. Epub 2016 May 7.

PMID:
27511844
23.

Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.

Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R.

Oncotarget. 2017 Mar 21;8(12):18726-18734. doi: 10.18632/oncotarget.9640.

24.

Involvement of calprotectin (S100A8/A9) in molecular pathways associated with HNSCC.

Khammanivong A, Sorenson BS, Ross KF, Dickerson EB, Hasina R, Lingen MW, Herzberg MC.

Oncotarget. 2016 Mar 22;7(12):14029-47. doi: 10.18632/oncotarget.7373.

25.

BCL-2 protects human and mouse Th17 cells from glucocorticoid-induced apoptosis.

Banuelos J, Shin S, Cao Y, Bochner BS, Morales-Nebreda L, Budinger GR, Zhou L, Li S, Xin J, Lingen MW, Dong C, Schleimer RP, Lu NZ.

Allergy. 2016 May;71(5):640-50. doi: 10.1111/all.12840. Epub 2016 Feb 4.

26.

The transcriptional profile of coronary arteritis in Kawasaki disease.

Rowley AH, Wylie KM, Kim KY, Pink AJ, Yang A, Reindel R, Baker SC, Shulman ST, Orenstein JM, Lingen MW, Weinstock GM, Wylie TN.

BMC Genomics. 2015 Dec 18;16:1076. doi: 10.1186/s12864-015-2323-5.

27.

Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.

William WN Jr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM.

JAMA Oncol. 2016 Feb;2(2):209-16. doi: 10.1001/jamaoncol.2015.4364.

28.

Next-gen tissue: preservation of molecular and morphological fidelity in prostate tissue.

Gillard M, Tom WR, Antic T, Paner GP, Lingen MW, VanderWeele DJ.

Am J Transl Res. 2015 Jul 15;7(7):1227-35. eCollection 2015.

29.

Quantitative proteomic analysis of microdissected oral epithelium for cancer biomarker discovery.

Xiao H, Langerman A, Zhang Y, Khalid O, Hu S, Cao CX, Lingen MW, Wong DTW.

Oral Oncol. 2015 Nov;51(11):1011-1019. doi: 10.1016/j.oraloncology.2015.08.008. Epub 2015 Aug 29.

PMID:
26321370
30.

Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis.

Zhong R, Bao R, Faber PW, Bindokas VP, Bechill J, Lingen MW, Spiotto MT.

Cancer Res. 2015 Sep 15;75(18):3958-3969. doi: 10.1158/0008-5472.CAN-15-0199. Epub 2015 Aug 20.

31.

Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions.

Macey R, Walsh T, Brocklehurst P, Kerr AR, Liu JL, Lingen MW, Ogden GR, Warnakulasuriya S, Scully C.

Cochrane Database Syst Rev. 2015 May 29;(5):CD010276. doi: 10.1002/14651858.CD010276.pub2. Review.

PMID:
26021841
32.

Welcome R. Bryan Bell, DDS, MD, FACS, FACD.

Lingen MW.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 May;119(5):485. doi: 10.1016/j.oooo.2015.02.001. Epub 2015 Feb 7. No abstract available.

PMID:
25804874
33.

AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.

Clin Cancer Res. 2015 Jun 1;21(11):2601-12. doi: 10.1158/1078-0432.CCR-14-2648. Epub 2015 Mar 12. Erratum in: Clin Cancer Res. 2018 Dec 1;24(23):6099.

34.

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.

Schechter RB, Nagilla M, Joseph L, Reddy P, Khattri A, Watson S, Locati LD, Licitra L, Greco A, Pelosi G, Carcangiu ML, Lingen MW, Seiwert TY, Cohen EE.

Cancer Lett. 2015 Apr 10;359(2):269-74. doi: 10.1016/j.canlet.2015.01.024. Epub 2015 Jan 29.

PMID:
25641339
35.

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.

Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY.

Clin Cancer Res. 2015 Feb 15;21(4):870-81. doi: 10.1158/1078-0432.CCR-14-2481. Epub 2014 Dec 9.

36.

Triple O has gone virtual!

Lingen MW.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Jan;119(1):1-2. doi: 10.1016/j.oooo.2014.10.001. Epub 2014 Oct 13. No abstract available.

PMID:
25482546
37.

Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.

Ferguson BD, Tretiakova MS, Lingen MW, Gill PS, Salgia R.

Growth Factors. 2014 Dec;32(6):202-6. doi: 10.3109/08977194.2014.980904. Epub 2014 Nov 13.

38.

Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma.

Tower JI, Lingen MW, Seiwert TY, Langerman A.

Am J Transl Res. 2014 Oct 11;6(5):548-57. eCollection 2014.

39.

Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma.

Khattri A, Zuo Z, Brägelmann J, Keck MK, El Dinali M, Brown CD, Stricker T, Munagala A, Cohen EE, Lingen MW, White KP, Vokes EE, Seiwert TY.

Oral Oncol. 2015 Jan;51(1):53-8. doi: 10.1016/j.oraloncology.2014.08.014. Epub 2014 Sep 23.

PMID:
25255959
40.

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.

Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, Brägelmann J, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS.

Clin Cancer Res. 2015 Feb 1;21(3):632-41. doi: 10.1158/1078-0432.CCR-13-3310. Epub 2014 Jul 23.

41.

DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer.

Seiwert TY, Wang X, Heitmann J, Villegas-Bergazzi V, Sprott K, Finn S, O'Regan E, Farrow AD, Weichselbaum RR, Lingen MW, Cohen EE, Stenson K, Weaver DT, Vokes EE.

PLoS One. 2014 Jul 14;9(7):e102112. doi: 10.1371/journal.pone.0102112. eCollection 2014.

42.

CD84 is markedly up-regulated in Kawasaki disease arteriopathy.

Reindel R, Bischof J, Kim KY, Orenstein JM, Soares MB, Baker SC, Shulman ST, Perlman EJ, Lingen MW, Pink AJ, Trevenen C, Rowley AH.

Clin Exp Immunol. 2014 Jul;177(1):203-11. doi: 10.1111/cei.12327.

43.

p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors.

Kuo WL, Sharifi MN, Lingen MW, Ahmed O, Liu J, Nagilla M, Macleod KF, Cohen EE.

PLoS One. 2014 Mar 5;9(3):e90171. doi: 10.1371/journal.pone.0090171. eCollection 2014.

44.

CD34 and α smooth muscle actin distinguish verrucous hyperplasia from verrucous carcinoma.

Paral KM, Taxy JB, Lingen MW.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Apr;117(4):477-82. doi: 10.1016/j.oooo.2013.12.401. Epub 2013 Dec 19.

45.

Periostin is upregulated in coronary arteriopathy in Kawasaki disease and is a potential diagnostic biomarker.

Reindel R, Kim KY, Baker SC, Shulman ST, Perlman EJ, Lingen MW, Trevenen C, Rowley AH.

Pediatr Infect Dis J. 2014 Jun;33(6):659-61. doi: 10.1097/INF.0000000000000233.

46.

Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.

Zhao L, Antic T, Witten D, Paner GP, Taxy JB, Husain A, Gwin K, Mirza MK, Lingen MW, Tretiakova MS.

Am J Surg Pathol. 2013 Dec;37(12):1876-81. doi: 10.1097/PAS.0b013e31829e2525.

PMID:
24121175
47.

Immunoprofiling of oral squamous cell carcinomas reveals high p63 and survivin expression.

Lauxen IS, Oliveira MG, Rados PV, Lingen MW, Nör JE, Sant'ana Filho M.

Oral Dis. 2014 Apr;20(3):e76-80. doi: 10.1111/odi.12136. Epub 2013 Jun 6.

48.

PTEN deficiency contributes to the development and progression of head and neck cancer.

Squarize CH, Castilho RM, Abrahao AC, Molinolo A, Lingen MW, Gutkind JS.

Neoplasia. 2013 May;15(5):461-71.

49.

Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing.

Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, Beckett MA, Lingen MW, Witt M, Weichselbaum RR, Fu YX.

J Immunol. 2013 Jun 1;190(11):5874-81. doi: 10.4049/jimmunol.1202612. Epub 2013 Apr 29.

50.

Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.

Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY.

Oral Oncol. 2013 Jun;49(6):525-33. doi: 10.1016/j.oraloncology.2013.02.003. Epub 2013 Mar 13.

PMID:
23490885

Supplemental Content

Loading ...
Support Center